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Background: It remains clinically important to identify ER positive breast cancers likely to respond to 
tamoxifen (TAM) and so we aimed to select a group of biomarkers able to predict response. We also assessed 
whether data from different sample types [tumor microarrays (TMAs) and core biopsies] or tumor sites could 
be combined for biomarker studies.
Methods: A total of 123 endocrine treatment naïve patients with known ER and HER2 status treated 
with TAM had paraffin-embedded tumor tissue available either as TMAs (n=102) or core biopsies (n=21). 
TMA cores were collected from three different tumor sites, two central and one peripheral. Ten biomarkers 
were evaluated by immunohistochemistry, for % positivity and/or H-Score, comprising: ER, HER2, Ki-
67, phosphorylated forms of ER (Ser118), IGF1R, PRAS40, Akt & MAPK (ERK1/2), and PTEN & 
androgen receptor expression (AR). Each tumor was analysed for Akt1 E17K somatic mutation using 
BEAMing technology. Patient outcome was assessed by clinical benefit (CB) rate & survival analyses [time to 
progression (TTP) and time to death (TTD)]. 
Results: There was no significant difference in % positivity or H-Score between central & peripheral 
tumor sites for all biomarkers examined. After False Discovery Rate (FDR) correction differences (P<0.05) 
were observed between the two central samples only for HER2 & pER118 and pPRAS40. However, 
differences in biomarker expression were common between core biopsies and TMAs. Only 2/123 (1.6%) 
tumors had Akt1 E17K mutations. Univariate and multivariate analyses identified that lower levels of PTEN 
and higher levels of Ki-67 (% positivity) were predictive of poor outcome (TTP & TTD) following TAM. 
Higher ER. lower Ki-67 and AR/ER ratio <2 predicted increased CB rate. 
Conclusions: There were few differences in marker expression between TMAs from different intra-
tumoral sites. More marked differences between TMAs and core biopsies suggest caution if combining 
such datasets. Loss of PTEN, a key regulator of the PI3K/Akt pathway, was the only RTK/kinase signaling 
biomarker related to poorer clinical outcome. PTEN along with ER & lower Ki-67 proved the most 
predictive markers for better outcome (TTP & TTD and/or CBR) following TAM treatment. 
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Introduction
Resistance to endocrine therapy (ET) is an ongoing clinical 
challenge in the treatment of estrogen receptor positive 
ER+ breast cancer (BC). Between 50–80% of ER+ patients 
initially show clinical benefit to ETs that target estrogen/
ER signaling (1,2). Tamoxifen (TAM), a SERM, is one ET 
that has been used for nearly 40 years in BC (3) and acts by 
competitively binding to the ER thus blocking the ability 
of estrogen to drive tumor growth (4). Many patients now 
receive aromatase inhibitor (AI) treatment, which acts 
by causing estrogen deprivation, yet TAM has not been 
superceded by AIs in every clinical scenario, e.g., remaining 
an important adjuvant ET in premenopausal patients. In 
postmenopausal patients, 10 years treatment with an AI 
has not been established as superior to 5 years. Thus, the 
best extended ET options in post-menopausal BC are still 
unclear and may incorporate TAM since all of the following 
have been shown in RCTs to be better than 5 years of TAM 
alone, i.e., (I) 10 years of TAM (ATLAS & aTTOM) (5,6)], 
(II) 5 years of TAM followed by 3–5 years of AI (MA17) (7) 
or (III) 5 years of AI (ATAC, BIG 1–98) (8). TAM still has 
a significant role in BC chemoprevention (9-12) where 
studies up to 20 years (9,11) provide data on its long-term 
efficacy vs. side-effects. It remains clinically-important to 
identify BCs most likely to be sensitive to TAM. 
Steroid hormone receptors, growth factor signaling and 
resistance to ET
Resistance can either be ‘de-novo’ (i.e., no evidence of 
hormone sensitivity—defined in the advanced setting as 
progression within 6 months of starting ET) or ‘acquired’ 
(i.e., in this setting, after a period of response/stable disease 
for at least 6 months the tumor progresses). In ER+ BC the 
proliferation marker Ki-67 is a prognostic tool that may be 
valuable in defining responsiveness to ET (13,14). 
It may be possible to define other molecular predictive 
biomarkers based on ET signalling. ER-alpha (ER) 
expression is commonly retained in ET resistance (15) 
and is mostly in its wild type form in BCs refractory to 
TAM since its mutation is enriched primarily in estrogen 
deprivation resistant patients where it is believed to 
promote a constitutively-active receptor (16-18). A second 
ER, ER beta, has five isoforms and while the data for ERβ 
is engaging it has not yet been established as a marker with 
clinical utility in breast cancer. For example, in one study 
of 177 postmenopausal women who received adjuvant 
tamoxifen, the recurrence-free interval was found to differ 
with respect to degree of nuclear ERβ1 expression (19). In 
another study from our own research group of 880 patients 
with primary breast cancer, nuclear ERβ2 and ERβ5, but 
not ERβ1, significantly correlated with OS and ERβ2 
additionally with DFS. ERβ2 also predicted response to 
endocrine therapy and correlated positively with ERα, 
progesterone receptor and androgen receptor (20). Not only 
were the tumor and clinical outcome correlations different 
between these two studies for ERβ1 but the positivity varied 
from 33% to 99% respectively, despite the fact both used 
the same mouse monoclonal antibody clone PPG5/10 which 
was raised against the unique COOH-terminal peptides of 
ERβ1. In a further study involving 911 patients with breast 
cancer, ERβ1 expression (again using this antibody) reported 
positivity in 89% of tumors (21). In this study, high ERβ1 
expression was a favourable prognostic marker, especially 
in chemotherapy treated patients, but not in the endocrine 
therapy-treated breast cancer patients. Furthermore, in 
a pre-surgical study comparing the effect of short-term 
tamoxifen or three doses of fulvestrant (50, 125 and 250 mg) 
versus placebo we previously reported significant changes in 
ERα, PR and Ki-67 (22). However, there was no significant 
difference between any of the endocrine arms and placebo 
in terms of either ERβ1 or ERβ2 (personal communication 
J Robertson). Therefore, while the role of ERβ in breast 
cancer continues to be explored (23) we did not include it as 
a biomarker in the present study but focussed on ERα.
Breast cancer models have helped reveal multiple potential 
mechanisms underpinning resistance (24). Cross talk between 
ER and deregulated growth factor-driven kinase signaling 
pathways has been most implicated (25,26), including 
subverting responsiveness to TAM (27). Such mechanisms 
have been proposed as a key focus for progress in overcoming 
endocrine resistance (28). Three membrane receptor tyrosine 
kinases (RTKs) with reported roles in cell proliferation in 
particular have been linked to TAM resistance: insulin-like 
growth factor (IGF) 1 receptor (IGF1R), epidermal growth 
factor receptor (EGFR), and HER2. Inhibition of such 
receptors can lead to restoration of the therapeutic effect 
of TAM (29). IGF1R has been reported in relation to the 
endocrine responsive phenotype (30). Blockade of the IGFR 
pathway with the monoclonal antibody Ganitumab showed 
a negative therapeutic impact (31). Downstream of such 
RTKs, PI3K signaling through hyper-activation of Akt 
plays an important role ER+ BC progression, being able 
to facilitate resistance to ET (32-37). An E17K mutation 
in AKT1 is also capable of constitutively-activating 
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this enzyme (38). Loss of the enzyme phosphatase and 
tensin homolog (PTEN) can furthermore result in Akt 
hyperactivity (39,40) and its loss has been associated with 
TAM resistance (30). Phosphorylation on Thr246 of 
Proline-rich Akt substrate of 40 kDA (PRAS40), an Akt 
substrate and indicator of PI3K pathway activation status 
(37,41), might also feasibly relate to worsened prognosis 
but to date there is a paucity of studies exploring the 
contribution for pPRAS40 in TAM resistant ER+ BC. 
Several routes exist for subsequent cross-talk between 
deregulated RTK/kinase pathways and ER, including 
ligand independent activation of ER (24). Nuclear ER 
phosphorylation of AF-1 residues including serine 118 and 
167 (pER118 and pER167 respectively) can be triggered by 
these kinase pathways. Non-genomic (plasma membrane) 
ER interacts with RTKs activating downstream kinases 
that can drive such ligand-independent nuclear ER 
phosphorylation. ERK1/2 MAP kinase (MAPK) has been 
linked to induced phosphorylation of ER’s serine 118 residue, 
thereby promoting hormone independent growth in models 
(42,43). Hyperactive Akt can phosphorylate ER on serine 
167, for example when driven by PTEN loss (40). Ligand-
independent ER activation in turn may enhance expression 
of growth factors (44,45). Such signaling can be causal in BC 
models resistant to ET (28) including TAM (44,45). 
An alternative nuclear steroid hormone receptor, the 
androgen receptor (AR), a relatively new marker in relation 
to BC response to ET, is potentially important (46). The 
expression of AR has been related to expression of ER (47) 
and subsequently in a larger series of BCs associated with 
multiple phenotypes and biomarkers (48). AR has also been 
reported as a prognostic marker (49). Thus, AR positive 
tumors are associated with luminal A disease (50), low grade 
tumors (50,51), and better outcome in patients with ER+ 
BC (49,50). In contrast, AR overexpression has been linked 
with TAM resistance in pre-clinical experiments (52,53); 
Cochrane et al. reported that the risk of TAM failure for 
patients with a nuclear AR/ER ratio ≥2 was 4 times that of 
the lower ratio subgroup (54).
To identify if any of these molecular markers implicated 
in steroid receptor and RTK/kinase pathways (including 
PI3K/Akt signaling) predicts response or resistance 
to TAM in patients with ER+ BC 10 biomarkers were 
immunohistochemically-evaluated. By including biopsy 
specimens and tumor microarrays (TMAs), as well as from 
different tumor locations, the study was able consider 
whether biomarker data derived from different intra-
tumoral locations or sample types can be combined for 
such studies. We present the following article in accordance 
with the MDAR checklist (available at http://dx.doi.
org/10.21037/tbcr-20-31).
Methods
Patients and immunohistochemical 
A total of 123 endocrine treatment naïve patients with 
known ER and HER2 status were treated with TAM and 
had clinical outcome data: 102 had their tumor samples 
in a tumor microarray format (TMAs) and 21 as core 
biopsies (Figure 1)]. An additional five patients with TMAs 
but no outcome data were included only in the analysis of 
biomarker expression in TMA samples from different intra-
tumoral locations (i.e., central and peripheral) (i.e., total 
TMA samples n=107). 
Patients reported here were commenced on TAM 
between 1983–2002. During the earlier part of this period 
patients with ER unknown tumors or even on occasion 
known ER negative indolent disease were given TAM. For 
this report, in keeping with the ASCO guidelines, ER+ has 
been defined as ≥1% of tumor cells staining positive (55). 
103/123 (84%) patients had ER+ tumors and of these 
83/103 patients had surgery as initial treatment of their 
tumors. For these 83 patients, three 0.6 mm TMA samples 
were prepared from two central and one peripheral regions 
from the resected tumor tissue block for each patient: 
these patients received no adjuvant ET and were treated 
with TAM when they developed recurrent, advanced BC. 
The remaining 20 ER+ patients who did not have initial 
surgery for their tumors had core biopsies only, and were 
treated with TAM as a primary ET: these were either elderly 
patients with primary BC and were being treated by primary 
ET or patients who presented with advanced BC for whom 
TAM was the initial ET. Survival analyses included only ER+ 
patients with TAM clinical outcome data (n=103) (Figure 1). 
Categorization by HER2 status is also shown in Figure 1. 
Clinical data included measurements for time to progression 
(TTP), time to death (TTD), duration of clinical benefit 
(DoCB), clinical benefit (CB) and objective response (OR).
All tissue evaluated was formalin-fixed paraffin-embedded 
(FFPE) tumor material and specimens and clinical data 
were provided by the University of Nottingham and City 
Hospital (now Queens University Hospital), Nottingham. 
The study was conducted in accordance with the 
Declaration of Helsinki (revised 2013) and the Harmonized 
Tripartite Guideline for Good Clinical Practice from the 
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Full biomarker dataset N=157
Introduced the pTEN data to the full biomarker dataset
Merge clinical dataTMA




Core HER2+ n=4 TMA HER2+ n=18Core HER2– n=17
9 patients without 
status – all only have 
pTEN measurement





Clinical data available for 44 core 
biopsy patient
Clinical data available for 106 TMA 
patient
Figure 1 The consort diagram.
International Conference on Harmonization. Informed 
consent was waived and archival tissues were used with 
approval of the Ethics Committee and R & D Committee. 
The research protocol had approved from Nottingham 
Research Ethics Committee (Ref: 2020313) and R & D 
approval from the hospital (Ref: 03H101).
Biomarker measurements were performed by the 
University of Nottingham, the Breast Cancer Molecular 
Pharmacology Group in Cardiff University, and the Division 
of Oncology and Pathology, Department of Clinical 
Sciences in Lund University, Sweden. Ten biomarkers 
were evaluated by immunohistochemical (IHC) staining 
(assessing % positivity and/or H-Score), reflecting steroid 
receptor and RTK-kinase signaling as well as proliferation, 
comprising: ER-alpha (ER), HER2, Ki-67, phosphorylated 
(p) forms of ERK1/2 MAPK, Akt, ER (Ser118), PRAS40, 
and IGF1R, and PTEN & AR expression. All assays were 
applied to the clinical BC TMAs and core biopsies, except 
PTEN which was measured on core biopsies and full tumor 
sections (FTS) and AR which was measured only on TMAs 
(Table 1). Table S1 details the monoclonal antibodies used, 
phosphorylation site detected and IHC. A minimum of 100 
tumor epithelial cells were required for assessment of the 
IHC marker staining. Eight IHC markers were evaluated 
in Cardiff University using antibodies for ER expression, 
pER118, pMAPK, Ki-67, HER2, pIGF1R, pPRAS40 and 
pAkt followed by assessment by consensus of 2 experienced 
personnel (JMW Gee, P Finlay) blinded to the clinical data. 
All assays were performed by running small batches of test 
slides, together with an in-house internal assay positive 
breast cancer control to monitor for adequate IHC assay 
staining performance in each assay and so ensure no marked 
inter-assay differences. Each TMA was run in separate assays 
along with a subset of the biopsy samples. PTEN staining 
was performed in Nottingham. For this, staining was assessed 
by one observer and an H-score measured. Equivocal or 
borderline cases were re-examined and a consensus score was 
reached with a second observer. AR staining was performed 
and assessed in Lund by one observer. PTEN and AR IHC 
methodologies are again shown in Table 1. Table 1 shows the 
cellular location of staining (n = nuclear, c = cytoplasmic, 
m = plasma membrane) evaluated and the scoring method 
for all biomarkers. Figure S1 shows examples of higher and 
weaker staining for the various markers.
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Each tumor was also analysed for Akt1 E17K somatic 
mutation using BEAMing (Beads, Emulsions, Amplification, 
and Magnetics) technology by Sysmex Inostics GmbH, 
Hamburg, Germany (56). 
Analysis cohorts
The analysis cohorts consisted of (I) ER+ patients only, (II) 
ER+ patients sub-grouped by HER2 status (i.e., luminal A: 
ER+/HER2− & luminal B ER+/HER2+) and iii) grouped 
according to tissue type (core biopsy or TMA; also TMA 
combined with core biopsy) (Figure 1). HER2m status was 
categorized into negative “0” ≤30% or positive “1” >30% 
according to % of 3+ complete membrane staining. For 
each patient, the clinical TAM outcome & levels of staining 
for each biomarker comprised the analysis data. 
Given the size of the dataset it was necessary to 
combine the IHC scores from the TMA and core biopsies 
for analysis versus outcome for each marker. Previous 
publications, including from our own unit, have reported 
that core biopsies and surgical excision specimens show 
good correlation for ER status (57-59) with the H-score 
only slightly lower (between 10–20 on a 0–300 scale) in the 
surgical specimen compared to the core biopsy (57,58). A 
meta-analysis of 21 published studies involving almost 2,500 
patients also reported good overall concordance between 
core and surgical excision of 92.8 % for ER and 85.2 % for 
PR (60). Fewer prior publications exist regarding biomarkers 
of RTK-kinase pathways (61), in particular phospho-specific 
markers compared according to type of sample, although 
one publication has reported some differences (62). 
In exploring biomarker relationship to TAM outcome 
it was thus first important to be aware of any impact of 
combining steroid receptor, RTK/kinase or proliferation 
data from the different types of sample in the present study. 
This was achieved by evaluating differences in staining for 
individual biomarkers between TMAs and core biopsies 
(which in this study was an inter-patient, inter-tumor 
comparison). To more robustly achieve this, the number of 
core biopsies for staining was further increased by including 
further diagnostic pre-treatment core biopsies that were 
available without clinical outcome data (thus giving a total 
number of cores for this analysis n=50). The results were 
evaluated by non-parametric testing (Wilcoxon test applies 
throughout) before false discovery rate (FDR) correction 
in an exploratory analysis of sample positivity rate and 
staining level within the TMAs versus core biopsies for 
the biomarkers. Exploratory correlations were evaluated 
between levels of the signaling biomarkers to gauge whether 
the biological observations noted were also rational for the 
Table 1 The biomarkers
Biomarker Locations H-score, TMA H-score, Core % Pos, TMA % Pos, Core
RTKs
HER2 Plasma membrane Yes Yes Yes Yes
pIGF1R Plasma membrane Yes Yes Yes Yes
Intracellular kinase signaling
pPRAS40 Cytoplasm & nucleus Yes Yes Yes Yes
pMAPK Cytoplasm & nucleus Yes Yes Yes Yes
pTEN* Cytoplasm Yes (*FTS) Yes Yes (*FTS) Yes
pAKT Cytoplasm & nucleus Yes Yes Yes Yes
Steroid hormone receptor
pER118 Nucleus Yes Yes Yes Yes
ER Nucleus Yes Yes Yes Yes
AR Nucleus Yes N/A Yes N/A
Proliferation
Ki-67 Nucleus No No Yes Yes
*, FTS-PTEN was measured on core biopsies and on full tissue sections rather than TMAs and was scored for % cells positive and H-score.
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combined TMA plus core biopsy sample set.
Biomarkers in TMAs (n=107) obtained from the two 
central and the peripheral regions of the tumors were 
similarly statistically-examined, this time to evaluate any 
biomarker differences according to sample location within 
a tumor (i.e., intra-patient, intra-tumoral comparison) and 
so gauge if sample location might influence biomarker 
findings. The two central and one peripheral value were 
subsequently combined to get a single TMA value for each 
patient by taking the mean of all three values (central a, 
central b, peripheral) for analysis versus outcome.
Statistical analysis of IHC biological (steroid receptor, RTK-
kinase and proliferation) endpoints versus patient outcome
The ability of the IHC biomarkers to predict response to TAM 
as measured by CB, TTP, and TTD was examined in the 
ER+ patient cohort and according to HER2 status or sample 
type. In addition to analyzing the full set of IHC markers, 3 
further analyses were performed examining a combination of 
ER & Ki-67, pAkt and pPRAS40 (as an indicator of active Akt 
signaling) and also analysis of AR/ER ratio. 
The potential role of the markers in prediction of response 
to TAM was explored through logistic and survival models of 
clinical outcomes. Univariate and multivariate methods were 
used to model the markers individually and in combination. 
Logistic regression and Cox proportional hazards models 
were used to model clinical benefit and survival endpoints 
respectively. FDR correction was applied to results 
from univariate analyses, and variable selection methods 
including regression trees were used to avoid over fitting the 
multivariate model. Bootstrap methods (resampling from 
the original data) and model selection based on AIC were 
used to validate variable selection for logistic models and the 
final model for survival analyses. Interquartile range (IQR) 
odds ratios and IQR hazard ratios are presented along with 
confidence intervals, illustrating difference between high and 
low (3rd and 1st quartiles) measures for each of the markers. 
In the absence of any predefined cut points, the 
biomarkers were considered continuous predictors. 
Significance was set at one sided with P<0.05.
Results
Exploratory analyses of biological (steroid receptor, RTK/
kinase & proliferation) IHC endpoints 
Analysis of the IHC biomarker positivity rate in core 
biopsy vs. TMA samples 
Table 2 includes the number (and %) of biopsy samples (core 
or TMA)—showing any degree of immuno-positivity for 
Table 2 Samples analysed for each biomarker by type of biopsy (TMA or Core), with [n (%)] of samples positive
Biomarker TMA: % Pos TMA: H-score Core: % Pos Core: H-score
ERn 103 [88 (85%)] 107 [88 (82%)] 50 [46 (92%)] 50 [46 (92%)]
HER2m 106 [97 (92%)] 107 [97 (91%)] 50 [48 (96%)] 50 [48 (96%)]
Ki-67 106 [95 (90%)] N/C 50 [48 (96%)] N/C
pAKTc 106 [78 (74%)] 107 [78 (73%)] 50 [39 (78%)] 50 [39 (78%)]
pAKTn 106 [73 (69%)] 107 [73 (68%)] 50 [41 (82%)] 50 [41 (82%)]
pER118n 102 [72 (71%)] 107 [72 (67%)] 50 [47 (94%)] 50 [47 (94%)]
pIGFR1131 100 [28 (28%)] 107 [28 (26%)] 50 [46 (92%)] 50 [46 (92%)]
pMAPkc 102 [54 (53%)] 107 [54 (50%)] 50 [44 (88%)] 50 [44 (88%)]
pMAPkn 102 [83 (81%)] 107 [83 (78%)] 50 [48 (96%)] 50 [48 (96%)]
pPRAS40c 101 [88 (87%)] 107 [88 (82%)] 50 [50 (100%)] 50 [50 (100%)]
pPRAS40n 101 [52 (51%)] 107 [52 (49%)] 50 [15 (30%)] 50 [15 (30%)]
PTEN 117 [98]* 117 [98]* 20 [19] 20 [19]
ARn 86 [72 (84%)] 86 [72 (84%)] N/C N/C
*, FTS-PTEN was measured on core biopsies and on full tissue sections rather than TMAs and was scored for % cells positive and H-score. 
N/C, no comparison possible.
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each marker (considering n, m or c staining localization). 
As stated above, 50 core biopsies and up to 107 TMAs 
(with or without clinical outcome data) were included in 
this exploratory analysis. pIGFRm had substantially more 
positive core biopsies than positive TMAs and for pAKTn, 
pER118n, pMAPKc, pMAPKn and pPRAS40c somewhat 
increased positivity rate was also seen in core biopsies. No 
marked discordance was noted for the % tumors showing 
any immunopositivity for total nuclear ER (ERn), HER2m, 
pAktc or Ki-67 between core biopsy vs. TMA sample types. 
Only pPRAS40n had a reduced % positivity rate in the core 
biopsies compared with TMA samples (Table 2). PTEN 
was measured on either FTS or core biopsies and therefore 
was not included in this comparison of TMAs versus core 
biopsies. AR was not measured in cores, but showed a 
substantial % nuclear positivity rate in the TMAs (Table 2).
Analysis of IHC biomarker staining level in core biopsy 
vs. TMA samples and inter-marker correlations in the 
combined dataset
The positive staining level (H-Score or %) in the TMAs 
compared with core biopsies was different for some of 
the biomarkers; when FDR correction was applied to the 
resultant individual Wilcoxon P values the hypothesis that 
% positivity or H-scores cannot be assumed to be the same 
was verified (Table 3). Staining values were generally lower 
in TMAs, and after FDR correction significant differences 
remained for pER118n, pIGF1Rm, pMAPKc, HER2m, 
pAktc and pPRAS40c, and for ER H-Score only, but 
there were no significant differences for pAktn, pMAPKn 
or pPRAS40n, or for ER or Ki-67 when measured by 
percentage positivity, between core biopsy and TMA samples. 
Exploratory analysis revealed several biologically-
expected significant correlations between markers in the 
combined biopsy cores and TMAs (Figure S2), notably 
between total and pER118n; for pMAPKn, pAktn and 
pPRAS40c with pER118n; between pAktc and pPRAS40c, 
and several for pIGF1Rm (including with HER2m, 
PRAS40c and pER118n). An inverse correlation was noted 
between ER expression and Ki-67 (Figure S2).
Comparing the IHC biomarkers in TMAs obtained 
from central & peripheral regions of tumors
Figure 2 show the box plots of % positivity and H-score 
Table 3 Tissue type and tissue location (FDR corrected)
Biomarker
TMA vs. Core Biopsy (FDR P value) Central vs. peripheral (FDR P value) Central a vs. central b (FDR P value)
% Positive H Score % Positive H Score % Positive H Score
ERn 0.29 <0.01 1 1 1 1
HER2m <0.01 <0.01 1 1 <0.05 0.23
Ki-67 1 N/C 1 N/C 0.24 N/C
pAKTc 0.27 0.04 1 1 0.81 0.53
pAKTn 1 0.18 0.66 0.40 1 1
pER118n <0.01 <0.01 0.10 0.35 <0.05 0.19
pIGFR1131m <0.01 <0.01 1 1 1 1
pMAPkc <0.01 <0.01 1 1 1 1
pMAPkn 1 0.34 1 1 0.81 1
pPRAS40c <0.01 <0.01 1 1 0.19 <0.05
pPRAS40n 0.07 0.12 1 1 1 1
ARn N/C N/C 1 1 0.81 1
PTEN* 1 0.08 N/C N/C N/C N/C
*, PTEN was measured on core biopsies and on full tissue sections rather than TMAs and was scored for % cells positive and H-score. N/C, 
no comparison possible.
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Figure 2 Box plots of % positivity and H-score.
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respectively comparing each of the different sample 
locations within each tumor for the biomarkers. After FDR 
correction there was no significant difference between the 
peripheral sample and the mean of the two central TMA 
samples for % positivity or H-Score of any of the markers 
(Table 3). Between the two central samples, there was a 
modest significant difference (P<0.05) detected for % 
positivity only for HER2m and pER118n (Table 3) while for 
H-score there was a modest significant difference (P<0.05) 
detected for pPRAS40c (Table 3). The lack of marked 
differences support feasibility of combining staining data for 
these biomarkers (including Ki-67) at the different tumor 
sites (as a mean) for analysis versus outcome
 
Analyses of Akt1 E17K somatic mutation
Only 2/123 (1.6%) tumors had Akt1 E17K mutations. 
Relationships between IHC biomarkers and tamoxifen 
outcome 
While the IHC biomarkers were scored by % positive 
staining and H-Score, the majority of the significant results 
versus outcome pertained to the % positive results (Table 
4). There were also too few patients in the HER2+ cohort 
to obtain conclusive data, so the following results refer only 
to the full ER+ combined TMA + Core biopsy cohort, the 
ER+ TMA only cohort, and the luminal A (ER+/HER2−, 
TMA + Core biopsy) cohort. 
Clinical benefit on tamoxifen
In the ER+ combined TMA + Core biopsy sample cohort, 
univariate models suggested there was an increased odds 
of clinical benefit (CB) associated with decreased levels of 
Ki-67 and increased levels of ERn expression, as measured 
by % positivity (Table 4). Given the differences in some 
biomarkers (other than Ki-67) between core biopsy and 
TMAs, studies were also performed within the TMA cohort 
alone, where the observation with ERn was retained. The 
significant association with Ki-67 was also seen in the 
luminal A (ER+/HER2−) cohort using the combined (ER+ 
TMA+ core biopsy) cohort. After adjustment for FDR no 
other significances for any of the RTK-kinase signaling 
molecules were obtained versus CB (Table 4). To avoid 
overfitting in the multivariate model, variable selection 
methods (regression trees of 1,000 bootstrapped samples) 
were used; the only markers included in the multivariate 
model were ERn and Ki-67, and also pPRAS40c and pAkt (as 
an indicator of active Akt signaling). Only Ki-67 and ER % 
positivity were retained as significant for CBR in the final 
multivariate model for the full sample cohort (Table 5). In 
the Luminal A cohort only the Ki-67 association remained 
when analyzing the full ER+ sample set (Table 4).
While AR alone was not predictive, the AR/ER staining 
ratio revealed 61 had a ratio <2, and 10 had a ratio ≥2. 
Fishers exact test showed that the odds of achieving CB was 
enriched in patients with an AR/ER ratio <2 [P<0.05, odds 
ratio 5.1 (1.01, 33.4)]. 
Survival endpoints following tamoxifen treatment
Univariate models were also fitted for TTP and TTD. After 
FDR correction a significant increased hazard of disease 
progression (TTP) and death (TTD) was seen in the full 
ER+ and also the Luminal A cohorts for those with higher 
Ki-67. Within the full ER+ cohort (FTS+ core biopsy or 
FTS only, but not for the luminal A cohort) a significantly 
increased risk of disease progression and death was found 
for those with lower PTEN % positivity levels (Table 4). No 
other associations were seen for the survival endpoints. 
Multivariate models analyses were performed using 
Table 4 % tumor cells positive univariate results (CBR, TTP & TTD)
Biomarker Cohort IQR OR/HR (95% CI)
CBR 
ER+, TMA + Core ERn OR 2.63 (1.43, 4.83)*
ER+, TMA + Core Ki-67 OR 0.45 (0.27, 0.78)*
ER+, HER2− Ki-67 OR 0.40 (0.21, 0.74)*
ER+, TMA only ERn OR 3.20 (1.57, 6.54)*
TTP
ER+, TMA + Core pTEN HR 0.83 (0.73, 0.94)*
ER+, TMA + Core Ki-67 HR 1.70 (1.24, 2.32)*
ER+, HER2− Ki-67 HR 1.76 (1.24, 2.49)*
ER+, TMA only pTEN HR 0.83 (0.73, 0.94)*
TTD 
ER+, TMA + Core pTEN HR 0.84 (0.74, 0.94)*
ER+, TMA + Core Ki-67 HR 1.64 (1.20, 2.23)*
ER+, HER2− Ki-67 HR 1.75 (1.21, 2.54)*
ER+, TMA only pTEN HR 0.84 (0.75, 0.95)*
*, FDR P value <0.05. pTEN was measured on core biopsies and 
on full tumor sections  rather than TMAs. Its staining was included  
in the analyses with all the other markers measure on TMAs.
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the full ER+ cohort, considering the Core biopsy + TMA 
combined or TMA alone samples, although as noted 
above pTEN was measured in FTS and core biopsies: in 
both analyses increased Ki-67 and decreased PTEN were 
predictive of TTP and TTD (Table 5). Only Ki-67 proved 
significant versus these endpoints in the Luminal A cohort. 
In contrast to the CB data, no significant results were seen 
for TTP and TTD in relation to AR/ER ratio. These 
results were validated by bootstrapping and model selection 
based on AIC. 
Discussion
This study adds to the literature on the impact of type 
of clinical sample and of intra-tumoral site of biopsy 
when assessing biomarkers as predictors of clinical utility 
in breast cancer. Even after FDR correction significant 
differences in staining level remained for the majority of 
markers according to sample type (pER118n, pIGF1Rm, 
pMAPKc, HER2m, pAktc and pPRAS40c and for ER 
H-Score only). There were no significant differences for 
pAktn, pMAPKn, pPRAS40n, Ki-67 or ER when assessed 
by percentage positivity or H-score between core biopsy 
and TMAs. This is an important and reassuring finding 
since ER and Ki-67 are two of the markers identified as 
significantly associated with clinical outcome in this study 
and associations with outcome have also been noted for Ki-
67 in sequential sample studies (13). Differences commonly 
noted in signaling marker staining for immunopositivity 
rate and level between core biopsies and TMAs (often 
staining higher in the former) may be related to differences 
in fixation/preparation of each type of sample influencing 
antigenicity and thus the subsequent IHC assay data. This 
has previously been suggested by other groups (61,62), 
who reported somewhat higher levels of selected AKT 
signaling elements and phospho-MAPK in core biopsies. 
It should however be appreciated that in the present study 
the core biopsy versus excision specimens were not a 
direct comparison from the same tumor and so differences 
reported here may, at least in part, also be due to differences 
in phenotype of tumors which had core biopsy (primary ET 
patients) versus TMAs constructed from surgically resected 
tumors. Importantly, however, there was no significant 
difference in Ki-67 between TMA and core samples. 
For all the biomarkers reported in the present study 
the findings suggest that the site biopsied within a tumor 
is not a critical issue: our analysis of multiple biomarkers 
was a direct comparison within the same tumor. This 
is important in interpreting the results of studies using 
percutaneous core biopsy material where differences in 
biomarkers between groups have been suggested may 
be due, at least in part, to the sampling of different sites 
within the tumors. Equally studies assessing the effect 
of drug therapies using sequential core biopsies in an 
Table 5 Tumor cells positive multivariate results (CBR, TTP & TTD)
Cohort IQR OR/HR (95% CI) IQR OR/HR (95% CI)
CBR
ER+, TMA + Core Ki-67: OR 0.5 (0.28, 0.9)* ERn: OR 2.25 (1.19, 4.27)*
TTP
ER+, TMA + Core Ki-67: HR 1.48 (1.06, 2.07)* pTEN: HR 0.83 (0.73, 0.94)*
ER+, HER2− Ki-67: HR 1.57 (1.09, 2.26)* pTEN: HR 0.81 (0.69, 0.94)*
ER+, TMA only Ki-67: HR 1.39 (1.02, 1.89)* pTEN: HR 0.83 (0.74, 0.95)*
ER+, TMA only HER2 Ki-67: HR 1.53 (1.05, 2.24)* pTEN: HR 0.79 (0.67, 0.94)*
TTD   
ER+, TMA + Core Ki-67: HR 1.45 (1.04, 2.01)* pTEN: HR 0.85 (0.75, 0.96)*
ER+, HER2− Ki-67: HR 1.60 (1.08, 2.37)* pTEN: HR 0.79 (0.65, 0.96)*
ER+, TMA only Ki-67: HR 1.42 (1.02, 1.98)* pTEN: HR 0.85 (0.76, 0.96)*
ER+, TMA only HER2− Ki-67: HR 1.57 (1.06, 2.35)* pTEN: HR 0.79 (0.65, 0.96)*
*, P value <0.05. pTEN was measured on core biopsies and on full tumor sections rather than TMAs. Its staining was included in the  
analyses with all the other markers measure on TMAs.
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individual (22,63) have reported differences in expression/
activity of the various steroid receptor and RTK/kinases. 
Our study would indicate that such differences are not 
due to sequential biopsies being taken from different sites 
within the tumor. These findings are in keeping with the 
study by Meric-Bernstam and colleagues who reported 
no significant difference in 7 biomarkers measured by 
IHC according to tumor location (62): Ki-67, PTEN & 
p4EBP1 T70 showed strong correlations between central 
and peripheral expression, pAktS473, pPRAS40 T246 and 
pS6 S240/244 showed moderate correlations, and only 
pS6 S235/236 showed a low correlation. This study also 
measured biomarkers by RPPA and reported that of 154 
markers measured, 132 (86%) were not statistically different 
between the tumor centre and periphery. Tramm and 
colleagues recently reported on 27 patients assessing five 
biomarkers in central and peripheral regions, each within 
two separate tumor blocks (64): there was almost perfect 
concordance for BCL2, E-cadherin and EGFR between 
the central and peripheral regions and moderate/substantial 
agreement for EMMPRIN and Ki-67. Nevertheless, it 
should be noted that the finding of similar biomarker 
expression in peripheral and central sites in a tumor 
remains a matter of debate. Douglas-Jones and colleagues 
reported differences in ER expression across the width 
of tumors (58). Likewise, Aleskandarany and colleagues 
reported heterogeneity of Ki-67 expression within a 
tumor (although this was between ‘full face’ sections from 
different primary tumor blocks rather than from central 
or peripheral TMA cores within the tumor) (65). There 
may also be some loss of antigen signal between core 
biopsies and surgical resected specimens due to technical 
factors, particularly for phosphorylated proteins (62): 
where antigen signal has been diminished this might 
provide some explanation for similarity in signal between 
different areas of the same resected tumor specimen. 
The above highlight the importance of describing the 
study methodology and technical aspects of biomarker 
assessment when trying to correlate biomarker expression 
with clinical utility. We found using univariate and 
multivariate analysis that measures of clinical response to 
TAM can be predicted by increased staining for ER, the 
PI3K/Akt pathway regulator PTEN, or lower Ki-67, either 
in combination or individually. This was seen in the full 
ER+ cohort. For the ER+ TMA + Core combined group 
PTEN, Ki-67 and ERn as measured by % positive staining 
were all predictive: ERn & Ki-67 predicted CBR whereas 
Ki-67 and PTEN predicted TTP and TTD. It should be 
noted that ER and Ki-67 were also two markers for which 
there was no evidence of difference between TMA and core 
biopsy samples (in terms of % positivity) or between central 
or peripheral sites of the tumor, indicating these may be a 
robust combination of predictive markers for TAM outcome 
irrespective of sample type. PTEN was measured on FTS 
and core biopsies, so there was no central versus peripheral 
TMA comparison for PTEN in our study. However, Meric-
Bernstam and colleagues (62) reported “strong correlation” 
between PTEN expression of central and peripheral 
samples, suggesting this may also be a reliable signaling 
marker. Within the luminal A cohort only decreased Ki-67 
was seen to be predictive of increased CB, TTP, and TTD 
while increased pTEN was predictive of an increased TTP 
& TTD. 
Our ER, PTEN and Ki-67 predictive biomarker findings 
were not influenced by AKT mutation status, since such 
mutation was very low in this BC (1.6%), a finding reflective 
of the literature since a positivity rate for AktE17K 
mutation frequencies of 6.3% has been reported (66), and 
where previous published literature ranges from 1.4–8.2 %, 
with a mean mutation frequency of 3.8% (67). 
With regards to AR/ER ratio, the patient numbers were 
small and so the relationship detected between the <2 ratio 
and clinical benefit of TAM should be viewed with caution. 
Nevertheless, since they are in agreement with studies from 
Cochrane and colleagues where AR/ER ratio correlates 
with clinical outcomes (54), our findings suggest further 
research would be worthwhile to confirm or refute whether 
there is a meaningful relationship between AR/ER ratio and 
TAM clinical outcome. 
Several biologically-plausible correlations were preserved 
between the signaling steroid receptor and RTK-kinase 
biomarkers in this TMA plus core biopsy series. Of note, 
the correlations between total ER and pER118n, and 
between pMAPKn and pER118n, are in keeping with ER 
signaling and kinase/ER cross talk via ER activation (42,43). 
Correlations were also seen between pAkt and pPRAS40, 
elements both lying in the PI3K/Akt signaling pathway. 
Furthermore, the inverse correlation noted between ER and 
Ki-67 has been previously observed (68). However, despite 
these reassuring biological correlations and the wealth of 
supportive preclinical data from ET resistant BC models, 
unfortunately other than PTEN we found none of the 
examined markers reflective of RTK-kinase signaling and its 
cross-talk with ER were related to TAM outcome clinically. 
On one hand this might be surprising since inhibition of 
the PI3KCA/Akt/mTOR pathway has been reported to 
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result in significant increases in TTP/PFS (69,70). In these 
other clinical studies, most of the patients had been heavily 
pre-treated. Equally there are studies where inhibitors of 
these pathways have shown no significant improvement 
in TTP/PFS (71,72). The fact that the present study 
included hormone naïve patients and also used primary 
tumor tissue, where the PI3KCA/Akt/mTOR pathway may 
not be as disrupted as in metastases (73-75), may explain 
why no further markers reflective of the Akt pathway were 
intrinsically associated with TAM resistance. This therefore 
is one limitation of this study and it again highlights the 
importance of obtaining tumor tissue immediately prior to 
a new treatment especially within future studies. Likewise, 
studies comparing the molecular phenotype of primary 
and metastases within the same patient are important to 
elucidate the issues related to using primary tumors to 
predict response at a much later time point. A recent meta-
analysis of 5,000 patients with HR+ advanced BC showed 
that liver visceral metastases have a worse outcome than 
other sites of metastases (76,77) suggesting it may also be 
important to biopsy metastases from different organ sites to 
best predict clinical outcome to targeted therapies.
It would be difficult to biopsy all sites of metastases in 
routine clinical practice but from a perspective of trying to 
understand mechanism of resistance this could be viewed as 
another potential limitation. Furthermore, biopsies taken 
prior to starting any treatment, whether from the original 
primary tumor or metastases, may allow prediction of 
response or ‘de-novo’ progression. However, to more fully 
understand the mechanisms of acquired resistance, which 
can occur over months to many years, multiple sequential 
tumor biopsies on treatment and at relapse must be studied 
(78-81). The present study therefore was not able to look 
for markers which would highlight potential mechanisms of 
acquired resistance. 
From a mechanistic perspective, the observation that 
EGFR/HER2/IGF1R signalling and its potential cross-talk 
via kinases with ER phosphorylation were not biomarkers 
of tamoxifen resistance in our study might also be explained 
by the abundance of further resistance mechanisms that 
have emerged from laboratory studies. For example, along 
with many changes in ER signalling (including changes 
in ER’s potential dimer partners, ER variants and ER 
coactivators such as AIB1 (82,83), the de-regulation of 
alternative kinase signalling pathways and transcription 
factors [e.g., FGFR (84,85)], changes in non-coding RNAs 
(86,87), cell cycle regulators and apoptotic machinery (88) 
are just some of the mechanisms that have been proposed 
to contribute to endocrine resistance. The establishment 
and use of breast cancer cell lines that are tamoxifen 
resistant in vitro has been valuable towards the discovery 
and verification of many resistance mechanisms, with some 
of these models also having substantial proliferation in the 
presence of tamoxifen (89) and in some instances reduced 
ER (90) and PTEN loss (29,91) as observed in the present 
clinical study. Indeed, several of the deregulated pathways, 
following promising pre-clinical studies, have progressed to 
being evaluated and (in the case of CDK4/6 inhibition (92) 
approval as therapeutic targets alongside endocrine 
agents. Studies of patient tumor DNA samples and more 
complex in vivo model systems are also linking endocrine 
resistance to tumor heterogeneity, underpinned by further 
mechanisms involving genetic/epigenetic events (93), tumor 
microenvironment and cancer stem cells (94,95). Some of 
these mechanisms are likely to be important contributors to 
the control of proliferative activity and might also influence 
ER level, limiting effectiveness of agents such as tamoxifen.
Conclusions
In conclusion, while we acknowledge the limitation of this 
analysis due to the available sample size our results in this 
study support previous work that high ER and low Ki-67 
are predictive of clinical utility in hormone naïve patients 
receiving TAM and also adds PTEN loss. Significantly, 
considering the findings in this study together with other 
studies of biopsy type and site (62), all three markers appear 
independent of sample type and tumor region, adding to the 
robustness of these markers in relation to TAM outcome. 
In contrast, for the remaining 7 markers, it is feasible 
that some of these markers might have had some value if 
measured within a more advanced phenotype, since type 
of sample and the disease setting may be critical in relation 
to prediction of ET response/ progression. It may be more 
informative for biomarkers to be assessed on biopsies taken 
just prior to a particular therapy, with analytical variables 
minimized, in order to best gauge prediction of response 
in that setting. This should be our aim in prospective 
randomized trials of new targeted treatments in advanced 
BC. Furthermore, it remains important that we continue to 
uncover potential new targets and relevant markers from the 
most promising of the mechanisms of resistance emerging 
in experimental studies. In the future, these should continue 
to be prioritized for evaluation alongside ER, Ki-67 and 
PTEN as potential biomarkers to aid in selecting patients 
most likely to derive durable tamoxifen benefit.
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